Dai Ishikawa

Dr. Dai Ishikawa

Department of Gastroenterology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DCDaniele Corridoni
Daniele Corridoni
AAAgne Antanaviciute
Agne Antanaviciute
TGTarun Gupta
Tarun Gupta
DFDavid Fawkner-Corbett
David Fawkner-Corbett
AAAnna Aulicino
Anna Aulicino
ASAlison Simmons
Alison Simmons

17 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KNKei Nomura
Kei Nomura
Dai IshikawaDai Ishikawa
Dai Ishikawa
KOKoki Okahara
Koki Okahara
SIShoko Ito
Shoko Ito
KHKeiichi Haga
Keiichi Haga
ANAkihito Nagahara
Akihito Nagahara
Fecal microbiota transplantation following triple-antibiotic therapy (amoxicillin/fosfomycin/metronidazole) improves dysbiosis caused by reduced Bacteroidetes diversity in patients with ulcerative colitis (UC). We investigated the correlation between Bacteroidetes species abundance and UC activity. Fecal samples from 34 healthy controls and 52 patients with active UC (Lichtiger’s clinical activity index ≥5 or Mayo endoscopic subscore ≥1) were subjected to next-generation sequencing with HSP60 as a target in bacterial metagenome analysis. A multiplex gene expression assay using colonoscopy-harvested mucosal tissues determined the involvement of Bacteroidetes species in the mucosal immune response. In patients with UC, six Bacteroides species exhibited significantly lower relative abundance, and twelve Bacteroidetes species were found significantly correlated with at least one metric of disease activity. The abundance of five Bacteroidetes species (Alistipes putredinis, Bacteroides stercoris, Bacteroides uniformis, Bacteroides rodentium, and Parabacteroides merdae) was correlated with three metrics, and their cumulative relative abundance was strongly correlated with the sum of Mayo endoscopic subscore (R = −0.71, p = 2 × 10−9). Five genes (TARP, C10ORF54, ITGAE, TNFSF9, and LCN2) associated with UC pathogenesis were expressed by the 12 key species. The loss of key species may exacerbate UC activity, serving as potential biomarkers.

Verified
Journal Article
Open access
PDF file
KOKoki Okahara
Koki Okahara
Dai IshikawaDai Ishikawa
Dai Ishikawa
KNKei Nomura
Kei Nomura
SIShoko Ito
Shoko Ito
KHKeiichi Haga
Keiichi Haga
ANAkihito Nagahara
Akihito Nagahara
We previously demonstrated that fresh fecal microbiota transplantation (FMT) following triple antibiotic therapy (amoxicillin, fosfomycin, metronidazole (AFM); A-FMT) resulted in effective colonization of Bacteroidetes species, leading to short-term clinical response in ulcerative colitis (UC). Its long-term efficacy and criteria for donor selection are unknown. Here, we analyzed the long-term efficacy of A-FMT compared to AFM monotherapy (mono-AFM). AFM was administered to patients with mild to severe UC for 2 weeks until 2 days before fresh FMT. Clinical response and efficacy maintenance were defined by the decrease and no exacerbation in clinical activity index. The population for intention-to-treat analysis comprised 92 patients (A-FMT, n = 55; mono-AFM, n = 37). Clinical response was observed at 4 weeks post-treatment (A-FMT, 56.3%; mono-AFM, 48.6%). Maintenance rate of responders at 24 months post-treatment was significantly higher with A-FMT than mono-AFM (p = 0.034). Significant differences in maintenance rate according to the age difference between donors and patients were observed. Additionally, sibling FMT had a significantly higher maintenance rate than parent–child FMT. Microbial analysis of patients who achieved long-term maintenance showed that some exhibited similarity to their donors, particularly Bacteroidetes species. Thus, A-FMT exhibited long-term efficacy. Therefore, matching between donors and UC patients may be helpful in effectively planning the FMT regimen.

11 May 2024 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
Dai IshikawaDai Ishikawa
Dai Ishikawa
XZXiaochen Zhang
Xiaochen Zhang
KNKei Nomura
Kei Nomura
TSTomoyoshi Shibuya
Tomoyoshi Shibuya
MHMariko Hojo
Mariko Hojo
ANAkihito Nagahara
Akihito Nagahara
Background: The proportion of certain Bacteroidota species decreased in patients with ulcerative colitis, and the recovery of Bacteroidota is associated with the efficacy of fecal microbiota transplantation therapy. We hypothesized that certain Bacteroidota may advance ulcerative colitis treatment. Accordingly, we aimed to evaluate the anti-inflammatory effects of Bacteroidota strains isolated from donors. Methods: Donors with proven efficacy of fecal microbiota transplantation for ulcerative colitis were selected, and Bacteroidota strains were isolated from their stools. The immune function of Bacteroidota isolates was evaluated through in vitro and in vivo studies. Results: Twenty-four Bacteroidota strains were isolated and identified. Using an in vitro interleukin (IL)-10 induction assay, we identified 4 Bacteroidota strains with remarkable IL-10-induction activity. Of these, an Alistipes putredinis strain exhibited anti-inflammatory effects in a mouse model of colitis induced by sodium dextran sulfate and oxazolone. However, 16S rRNA gene-based sequencing analysis of A. putredinis cultures in the in vivo study revealed unexpected Veillonella strain contamination. A second in vitro study confirmed that the coculture exhibited an even more potent IL-10-inducing activity. Furthermore, the production of A. putredinis–induced IL-10 was likely mediated via toll-like receptor 2 signaling. Conclusions: This study demonstrated that A. putredinis, a representative Bacteroidota species, exhibits anti-inflammatory effects in vivo and in vitro; however, the effects of other Bacteroidota species remain unexplored. Our fecal microbiota transplantation-based reverse translation approach using promising bacterial species may represent a breakthrough in microbiome drug development for controlling dysbiosis during ulcerative colitis.

14 August 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
Dai IshikawaDai Ishikawa
Dai Ishikawa
TSTakashi Sasaki
Takashi Sasaki
MTMasahito Takahashi
Masahito Takahashi
KKKyoko Kuwahara-Arai
Kyoko Kuwahara-Arai
KHKeiichi Haga
Keiichi Haga
ANAkihito Nagahara
Akihito Nagahara
We previously reported that fresh fecal microbiota transplantation (FMT) after triple-antibiotic therapy (amoxicillin, fosfomycin, and metronidazole [AFM]; A-FMT) synergistically contributed to the recovery of phylum Bacteroidetes composition associated with the endoscopic severity and treatment efficacy of ulcerative colitis (UC). Here, we performed further microbial analyses using a higher-resolution method to identify the key bacterial species in UC and determine whether viable Bacteroidetes species from donor feces were successfully colonized by A-FMT. The taxonomic composition of Bacteroidetes in 25 healthy donors and 27 UC patients at baseline was compared at the species level using a heat-shock protein (hsp) 60–based microbiome method. Microbiota alterations before and after treatment of UC patients were also analyzed in 24 cases (n = 17 A-FMT; n = 3 mono-AFM; n = 4 mono-FMT). We found species-level dysbiosis within the phylum Bacteroidetes in UC samples, which was associated with reduced species diversity, resulting from hyperproliferation and hypoproliferation of particular species. Moreover, in responders treated with A-FMT, diversity was significantly recovered at 4 weeks after a fresh round of FMT, after which high degrees of similarity in Bacteroidetes species composition among recipients and donors were observed. A-FMT alleviated intestinal dysbiosis, which is caused by the loss of Bacteroidetes species diversity in patients with UC. Eradication of dysbiotic indigenous Bacteroidetes species by AFM pretreatment might promote the colonization of viable Bacteroidetes cells, thereby improving the intestinal microbiota dysbiosis induced by UC. Our findings serve as a basis for further investigations into the mechanisms of FMT.

29 November 2018 in Journal of Applied Microbiology
Verified
Journal Article
Open access
PDF file
MTM. Takahashi
M. Takahashi
Dai IshikawaDai Ishikawa
Dai Ishikawa
TST. Sasaki
T. Sasaki
YLY.J. Lu
Y.J. Lu
KKK. Kuwahara-Arai
K. Kuwahara-Arai
ANA. Nagahara
A. Nagahara
Aims There has been growing interest in faecal microbiota transplantation (FMT) as treatment. Although, frozen donor faeces preserved at −20°C has been widely used for practical advantages, freezing at −20°C can affect bacterial viability. Adequacy evaluation of fresh and frozen faeces as the transplant is necessary for the methodological improvement of FMT. Methods and Results The viable bacterial compositions of faecal specimens under fresh and freezing conditions were compared by a microbiome analysis using propidium monoazide (PMA microbiome). In addition, recovery abilities from bacterial reduction by antibiotics were compared between fresh and frozen FMT using a murine model. PMA microbiome results suggested that freezing and freeze‐thawing did not significantly affect in vitro faecal bacterial viability. However, the recovery effect from antimicrobial cleansing in frozen FMT was reduced in a freezing time‐dependent manner, especially prominent in Actinobacteria and Bacteroidetes phyla. Conclusions Short‐term freezing preservation of faeces exhibited maintenance of enteric colonization ability in frozen FMT in comparison to 1 month −20°C‐preservation. Significance and Impact of the Study Long‐term −20°C‐preservation of transplanted faeces can result in instability of the clinical outcome in FMT therapy. The standardization of practical procedures of FMT therapy according to disease types is desirable.